Tonix Pharmaceuticals Holding (TNXP) Gains from Investment Securities (2024)
Tonix Pharmaceuticals Holding's (TNXP) quarterly Gains from Investment Securities came in at $855000.0 in Q2 2024, up 112.21% quarter-over-quarter from -$7.0 million in Q1 2024.
Tonix Pharmaceuticals Holding (TNXP) Gains from Investment Securities (2024) Analysis & Trends
Tonix Pharmaceuticals Holding's Gains from Investment Securities history runs 1 years deep, the most recent figure standing at $855000.0 for Q2 2024.
- On a quarterly basis, Gains from Investment Securities changed N/A year-over-year to $855000.0 in Q2 2024; TTM through Dec 2024 was -$6.1 million, a N/A change from a year earlier, with the FY2024 full-year figure at -$6.1 million, down 2273.14% from the prior year.
- Gains from Investment Securities climbed to $855000.0 in Q2 2024 per TNXP's latest filing, from -$7.0 million in the prior quarter.
- Across five years, Gains from Investment Securities topped out at $855000.0 in Q2 2024 and bottomed at -$7.0 million in Q1 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,861.65 Bn | 66,861.36 Bn | - |
| 2 | Nanobiotix | 1,910.87 Bn | 1,910.81 Bn | - |
| 3 | Akari Therapeutics | 989.71 Bn | 989.71 Bn | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 69.90 Bn | 61.14 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.74 Bn | 62.74 Bn | - |
| 8 | Argenx Se | 55.83 Bn | 50.65 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.46 Bn | 37.46 Bn | - |
| 10 | Tonix Pharmaceuticals Holding | 141.18 Mn | 141.18 Mn | 5.30 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2024 | 855,000.00 |
| Jun 30, 2024 | 855,000.00 |
| Mar 31, 2024 | -7.01 Mn |
| Mar 31, 2024 | -7.01 Mn |